Managed entry agreements and funding for expensive therapies /
Mondher Toumi, Szymon Jaroslawski.
- First edition.
- 1 online resource.
- Pharmaceuticals, health economics and market access .
Includes bibliographical references and index.
Introduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK -- a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements.
"Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"--